Non-High-Density Lipoprotein Cholesterol and Guidelines for Cholesterol Lowering in Recent History.
Stanley S Levinson
https://pubmed.ncbi.nlm.nih.gov/31147695Actively Recruiting
Phase 4
Age: 18Years - 65Years
All Genders
ID06765265
Impact of Atorvastatin Versus Rosuvastatin on 25 Hydroxy Vitamin D Levels in Patients With Acute Coronary Syndrome
Led by King Edward Medical University · Updated on 2025-03-11
152
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
This clinical trial involves patients with acute coronary syndrome who have normal Vitamin D levels. The study aims to evaluate how two different drugs, Atorvastatin and Rosuvastatin, affect Vitamin D levels over six months. Researchers will compare these drugs to understand their impact on increasing Vitamin D in this patient group. Participants will be randomly assigned to one of two groups: one receiving Atorvastatin 40 mg once daily, and the other receiving Rosuvastatin 20 mg daily. Treatment will last for 24 weeks, after which Vitamin D levels will be measured to assess any changes caused by the medications. Throughout the study, patients will have their blood tested to measure Vitamin D levels at 24 weeks. Lipid profiles will also be checked at 4 and 24 weeks to monitor changes. The total participation duration is about six months, during which patients will be closely monitored for treatment effects and safety.
CONDITIONS
Brief Title
Impact of Atorvastatin Versus Rosuvastatin on 25 Hydroxy Vitamin D Levels in Patients With Acute Coronary Syndrome
Who Can Participate
Age: 18Years - 65Years
All Genders
Eligibility Criteria
You may qualify if you...
- Diagnosis of acute coronary syndrome
- 25 OH-Vitamin D levels between 30 and 70 ng/ml
- Age between 18 and 65 years
You will not qualify if you...
- Hypercalcemia
- Hypocalcemia
- Pregnancy
- Lactation
- Hypersensitivity to statins
- Hypothyroidism
- Deranged liver function tests and renal function tests
- Use of Vitamin D supplements, lipid lowering drugs, anti-obesity drugs, or corticosteroids within the last 3 months
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Treatment
Duration - 24 weeks
Participants receive either Atorvastatin 40 mg daily or Rosuvastatin 20 mg daily for 24 weeks.
Visits at 4 weeks and 24 weeks for lipid profile and vitamin D level assessments
Trial Site Locations
Total: 1 location
1
King Edward Medical University
Lahore, Punjab Province, Pakistan, 54000
Actively Recruiting
Loading map...
Research Team
A
Ali Hussnain
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
Atorvastatin increases 25-hydroxy vitamin D concentrations in patients with polycystic ovary syndrome.
Thozhukat Sathyapalan, John Shepherd, Charlotte Arnett...
https://pubmed.ncbi.nlm.nih.gov/20817794Effect of simvastatin and atorvastatin on serum vitamin d and bone mineral density in hypercholesterolemic patients: a cross-sectional study.
Abrar Thabit, Abdullah Alhifany, Razan Alsheikh...
https://pubmed.ncbi.nlm.nih.gov/25197610Comparative Effect of Atorvastatin and Rosuvastatin on 25-hydroxy-Vitamin D Levels in Non-diabetic Patients with Dyslipidaemia: A Prospective Randomized Open-label Pilot Study.
Panagiotis Anagnostis, Fotini Adamidou, Aristidis Slavakis...
https://pubmed.ncbi.nlm.nih.gov/25110531To study impact of treatment with Rosuvastatin versus Atorvastatin on 25 hydroxy Vitamin D concentrations among adult Indian men- a randomized control trial.
Vivek G Patwardhan, Zulf M Mughal, Raja Padidela...
https://pubmed.ncbi.nlm.nih.gov/33283767Impact of Statin Therapy on Plasma Vitamin D Levels: A Systematic Review and Meta-Analysis.
Amirhossein Sahebkar, Zeljko Reiner, Luis E Simental-Mendia...
https://pubmed.ncbi.nlm.nih.gov/27719645Possible mechanisms of interaction between statins and vitamin D.
S Bhattacharyya, K Bhattacharyya, A Maitra
https://pubmed.ncbi.nlm.nih.gov/22323613The Vitamin D Assessment (ViDA) study - Design and main findings.
Robert Scragg
https://pubmed.ncbi.nlm.nih.gov/31809866Impact of high-dose statins on vitamin D levels and platelet function in patients with coronary artery disease.
Monica Verdoia, Patrizia Pergolini, Roberta Rolla...
https://pubmed.ncbi.nlm.nih.gov/28068529